Article: Serono Obtains First Designation Under New EC Regulation on Orphan Products.

Application for European Marketing Authorization for Serostim(R)

to be Submitted by Year-End

GENEVA, Sept. 13 /PRNewswire/ --

Serono S.A. (SWX Swiss Exchange: SEO and NYSE: SRA) announced today that the European Commission has granted Orphan Medicinal Product (OMP) designation to Serono's recombinant human growth hormone product, Serostim(R), for the treatment of AIDS wasting. This is the first such designation under the new EC Regulation on orphan medicinal products which was passed in January 2000. Serono intends to submit an application for EU marketing authorization to the European Medicines Evaluation Agency (EMEA) by year-end.

...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!